Item Type | Name |
Concept
|
Melanoma
|
Academic Article
|
Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater.
|
Academic Article
|
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
|
Academic Article
|
Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.
|
Academic Article
|
TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates MMP-1 Expression in Human Melanoma Cells.
|
Academic Article
|
Altered drainage patterns in patients with melanoma and previous axillary dissection.
|
Academic Article
|
Metastatic melanoma causing jejunal intussusception.
|
Academic Article
|
Malignant melanoma of the gallbladder: a report of two cases and review of the literature.
|
Academic Article
|
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.
|
Academic Article
|
Lymphoscintigraphy in cutaneous melanoma: an updated total body atlas of sentinel node mapping.
|
Academic Article
|
Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant?
|
Academic Article
|
Outcomes in patients with mucosal melanomas.
|
Academic Article
|
Contrast-enhanced sonography for detection of secondary lymph nodes in a melanoma tumor animal model.
|
Academic Article
|
Melanoma.
|
Academic Article
|
Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma.
|
Academic Article
|
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASÂ Melanoma.
|
Academic Article
|
Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.
|
Academic Article
|
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
|
Academic Article
|
Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma.
|
Academic Article
|
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.
|
Academic Article
|
1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.
|
Academic Article
|
Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.
|
Academic Article
|
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
|
Academic Article
|
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
|
Academic Article
|
The next generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.
|
Academic Article
|
Consecutive Case Series of Melanoma Sentinel Node Biopsy for Lymphoseek Compared to Sulfur Colloids.
|
Academic Article
|
Precision Medicine in the Treatment of Melanoma.
|
Academic Article
|
FOXD3 Regulates VISTA Expression in Melanoma.
|
Academic Article
|
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
|
Academic Article
|
Margins of Melanoma Excision and Modifications to Standards.
|
Academic Article
|
ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?
|
Academic Article
|
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
|
Academic Article
|
Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
|
Academic Article
|
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
|
Academic Article
|
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
|
Academic Article
|
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
|
Academic Article
|
How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent.
|
Academic Article
|
COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States.
|
Academic Article
|
Family Attitudes and Communication about Sun Protection and Sun Protection Practices among Young Adult Melanoma Survivors and Their Family Members.
|